 concomit pelvic irradi mitomycin treatment advanc cervic carcinoma phase II studi late figo stage iib stage iii patient extern beam radiotherapi day week cm parallel pelvic field first patient Gy mid-plan dose fraction day last patient Gy fraction intracavitari boost Gy fraction day first patient concomit maximum g/day mitomycin maximum mg patient who grade cytopenia abl full dose intens dose day day treatment morbid reduc chemotherapi intens compar radiotherapi median follow-up month median surviv month result histor control radiat method two-year surviv late stage iib patient combin radiotherapi stage iii two-year pelvic control late stage iib combin stage iii contrast report centr result overal signific improv radiotherapi phase iii studi practic